Compare RVSB & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | RLYB |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.9M | 89.2M |
| IPO Year | 1997 | 2021 |
| Metric | RVSB | RLYB |
|---|---|---|
| Price | $5.28 | $16.90 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 50.7K | 12.2K |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.08 | ★ 6.16 |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $53.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.50 | ★ $2.75 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $4.81 | $0.48 |
| 52 Week High | $6.22 | $17.57 |
| Indicator | RVSB | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 57.65 |
| Support Level | $5.01 | $16.51 |
| Resistance Level | $5.56 | $17.34 |
| Average True Range (ATR) | 0.10 | 0.45 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 75.93 | 50.00 |
Riverview Bancorp Inc is the bank holding company. The Company's operations are managed along two operating segments, consisting of banking operations performed by the Bank and trust and investment services performed by the Trust Company. The Bank is engaged mainly in the business of attracting deposits from the general public and using such funds, together with other borrowings, to make various commercial business, commercial real estate, land, multi-family real estate, real estate construction and consumer loans. Additionally, the Trust Company offers trust and investment services. It has single operating segment.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.